RCS - Roquefort Theraptcs. - STAT-6 siRNA Presentation

Roquefort TherapeuticsAnnouncement

06/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241106:nRSF0532La&default-theme=true

RNS Number : 0532L  Roquefort Therapeutics PLC  06 November 2024

6 November 2024

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

STAT-6 siRNA Presentation at Advanced Therapy Development Congress

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on developing first in class medicines in the high value and high
growth immunology and oncology markets, is pleased to announce that the latest
experimental results for its STAT-6 siRNA program will be presented at the
Advanced Therapy Development Congress in London today.

 

STAT-6 siRNA Immunology / Oncology Medicine

siRNA therapeutics are an innovative new class of medicines based on RNA
interference (RNAi), whereby a gene is downregulated by disrupting its
messaging machinery, which was recognised with the 2006 Nobel Prize in
Physiology or Medicine. Roquefort Therapeutics' siRNA programs target STAT-6.
Signal Transducer and Activator of Transcription (STAT) proteins are both
signalling proteins and transcription factors that play a role in cell growth,
differentiation and function. STAT-6 is a key nodal transcription factor that
selectively mediates downstream signalling of IL-4 and IL-13, dominant and
central cytokines in the pathophysiology of Type 2 inflammatory diseases 1 .

 

As previously announced, Roquefort Therapeutic's siRNA programs have
demonstrated in vivo proof of concept and efficacy in oncology. This new set
of experiments investigated the use of the siRNA in the inflammation and
immunology ("I&I") field. STAT-6 is a novel I&I target validated by
Sanofi and Recludix Pharma through a significant ($100M) licensing transaction
in 2023(1). Our preliminary experiments demonstrated a significant reduction
in the levels of total STAT-6.

 

Presentation of STAT6 siRNA results at the Advanced Therapy Development
Congress

At the Advanced Therapy Development Congress today, the Company will present
the new results of the STAT-6 siRNA experiments in the I&I indication in a
scientific presentation titled Development of First-In-Class Advanced
Therapies For Immunology and Oncology.

 

The results presented today show that in a validated THP-1 model of I&I
disease, the STAT-6 siRNA dampened the immune response. Following IL-4
stimulation, the THP-1 cells were treated with siRNA eliciting an ~10 fold
reduction in total STAT-6 with a corresponding reduction in phospho-STAT-6 and
modification of the key biomarkers CCL-17 and CD-23.

 

Roquefort Therapeutics CEO Ajan Reginald commented:

"The results presented today highlight the Company's internal research and
development expertise in the Immunology and Inflammation field and the potency
of our siRNA program, in the highly attractive STAT-6 niche. A number of
leading Biotech companies have focused their research in the STAT-6 field and
so, we sought advice and designed our experiments based on feedback from our
potential Pharma partners. The results demonstrate our siRNA is highly
competitive in a head-to-head comparison with the leading STAT-6 companies,
with potentially better absolute efficacy.

 

These are the types of results we were seeking to validate our business model
of discovering early breakthrough innovation from which we develop medicines
that are highly attractive to Big Pharma. We are progressing with the
Company's near-term imperative, which remains, to complete meaningful
partnerships with one or more Big Pharma companies."

ENDS

Enquiries:
 Roquefort Therapeutics plc                      +44 (0)20 3918 8633
 Stephen West (Chairman) / Ajan Reginald (CEO)
 SP Angel Corporate Finance LLP (Broker)         +44 (0) 20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Buchanan (Public Relations)                     +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper / George Beale
 Peak IR (Investor Relations)                    +33 (0)7 44 44 15 42

 Seb Wykeham

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing first in class drugs in the high value and high growth immunology
and oncology markets prior to partnering with big pharma.

 

Roquefort Therapeutics' portfolio consists of five novel patent-protected
pre-clinical anti-cancer medicines.  The highly complementary profile of five
best-in-class medicines consists of:

·    Midkine antibodies with significant in vivo efficacy and toxicology
studies;

·    Midkine RNA therapeutics with novel anti-cancer gene editing action;

·    Midkine mRNA therapeutics with novel anti-cancer approach;

·    STAT-6 siRNA therapeutics targeting solid tumours with
significant in vivo efficacy; and

·    MK cell therapy with direct and NK cell-mediated anti-cancer action

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)
 and @RoquefortTherap on X (formerly Twitter).

 

 1 
https://recludixpharma.com/recludix-pharma-enters-into-a-strategic-collaboration-with-sanofi-to-advance-novel-oral-stat6-inhibitor-in-multiple-immunological-and-inflammatory-indications/

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQELFBZFLLFBV